Table 1. Case series summary for pediatric patients who converted to perampanel monotherapy during Study 311

	Patient 1	Patient 2	Patient 3	Patient 4
Age, years	7	4	10	9
M/F	F	F	M	M
Race	Caucasian	Black or African American	Asian	Caucasian
Disease cohort	PGTCS	POS (without SGS)	POS (without SGS)	POS (without SGS)
Time since diagnosis, years	7.9	2.9	5.2	3.9
Concomitant ASMs at Baseline	Phenytoin	Rufinamide, lacosamide	Oxcarbazepine	Oxcarbazepine
Received concomitant EIASMs (Y/N)	Y	N	Y	Y
Concomitant ASMs end date	13 Aug 2018	30 Nov 2017	19 Jan 2018	14 May 2018
Perampanel treatment				
Start date	13 Dec 2017	04 May 2017	18 Jul 2017	31 Oct 2017
Stop date	09 Dec 2018	02 May 2018	19 Jun 2018	01 Nov 2018
Total duration of exposure, days	362	364	337	367
Adjunctive therapy duration, days	244	211	186	196
Monotherapy duration, days	118	153	151	171
Dose at the end of the Core Study, mg/day	6	8	14	6
Dose at conversion to monotherapy, mg/day	6	8	14	5
Dose at the end of Extension A, mg/day	4	8	14	4

ASM, anti-seizure medication; EIASM, enzyme-inducing anti-seizure medication; F, female; M, male; N, no; PGTCS, primary generalized tonic-clonic seizures; POS, partial-onset seizures; SGS, secondarily generalized seizures; Y, yes